Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Intellia Therapeutics is a clinical-stage gene editing company developing curative treatments for genetic diseases and cancers. Their main products are in vivo gene editing therapies like NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema, alongside engineered cell therapies. The company is a leader in applying CRISPR/Cas9 technology to create novel genomic medicines.
AI-generated summary. Not investment advice.